Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2771158 | 0.93 | NR1H4 (0.61) | NR1H4MRGPRX4 | |
| SCHEMBL2771604 | 0.87 | NR1H4 (0.59) | NR1H4MRGPRX4 | |
| SCHEMBL2769940 | 0.87 | NR1H4 (0.50) | NR1H4MRGPRX4SMN1; SMN2 | |
| SCHEMBL498248 | 0.87 | NR1H4 (0.52) | NR1H4NR1H2NR1H3MRGPRX4CYSLTR1 | |
| SCHEMBL2772298 | 0.86 | NR1H4 (0.54) | NR1H4NR1H2NR1H3MRGPRX4NPBWR1 | |
| SCHEMBL4032850 | 0.84 | NR1H4 (0.52) | NR1H4NR1H2NR1H3MRGPRX4NPBWR1 | |
| SCHEMBL2772140 | 0.84 | NR1H4 (0.52) | NR1H4NR1H2NR1H3MRGPRX4 | |
| SCHEMBL4042349 | 0.84 | NR1H4 (0.52) | NR1H4NR1H2NR1H3MRGPRX4NPBWR1 | |
| SCHEMBL3764857 | 0.81 | NR1H4 (0.55) | NR1H4MRGPRX4NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL498092 | 0.80 | NR1H4 (0.53) | NR1H4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | NR1H4 1/4885NR1H2 6/4885NR1H3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.